SCHEMBL4059707

SCHEMBL4059707

COc1ccc(-c2nc3ccc(-c4ccccc4C(F)(F)F)cc3o2)cc1OC

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.62
KDM4E B2RXH2 3/20 0.51
ALOX5 P09917 1/20 0.51
PTGS2 P35354 3/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
RAB9A P51151 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
TSHR P16473 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 1/20 0.48
GPR119 Q8TDV5 2/20 0.46
BACE1 P56817 1/20 0.44
PDE4A P27815 1/20 0.43
UTRN P46939 1/20 0.43
S1PR1 P21453 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4052391 0.90 NPC1 (0.49) NPC1KDM4EPTGS2ALDH1A1HPGD
SCHEMBL4053287 0.89 GPR119 (0.54) NPC1PTGS2TSHRHSD17B10GPR119
SCHEMBL4053451 0.86 NPC1 (0.52) NPC1KDM4EALDH1A1RAB9ASMN1; SMN2
SCHEMBL4051500 0.86 NPC1 (0.54) NPC1KDM4EALDH1A1HPGDRAB9A
SCHEMBL4052778 0.85 NPC1 (0.67) NPC1KDM4EALOX5PTGS2ALDH1A1
SCHEMBL4058082 0.83 BACE1 (0.51) NPC1KDM4EALDH1A1HPGDRAB9A
SCHEMBL4053408 0.82 NPC1 (0.51) NPC1KDM4EALDH1A1HPGDRAB9A
SCHEMBL4051587 0.81 VSIR (0.51) NPC1KDM4EALDH1A1HPGDRAB9A
SCHEMBL4057762 0.81 BACE1 (0.46) KDM4EBACE1UTRNS1PR1
SCHEMBL4059846 0.79 P2RY14 (0.47) NPC1RAB9ASMN1; SMN2GPR119BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NPC1 4740/4885KDM4E 496/4885ALOX5 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.